Pfizer's Tukysa Approved for Early HER2-Positive Breast Cancer Treatment

The FDA has granted first-line approval for Pfizer's drug Tukysa (tucatinib) in combination therapy for HER2-positive breast cancer. This decision, based on the HER2Climb-05 trial, allows the tyrosine kinase inhibitor to be used earlier in the disease course, potentially delaying progression and expanding treatment options for a larger patient population.